Skip to main navigation Skip to search Skip to main content

Recent updates on the development of ganetespib as a Hsp90 inhibitor

  • Jungwon University

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Heat shock protein 90 (Hsp90) plays a critical role in the maintenance of multiple oncogenic pathways and is a required protein for folding and stability of many oncoproteins that are related to the growth, proliferation, and survival of many kinds of cancers. Ganetespib (STA-9090) is a potent, synthetic, small molecule inhibitor of Hsp90, and its binding to Hsp90 is known to result in the degradation of its client proteins and subsequent death of cancer cells. This article provides a review of ganetespib as one of the leading Hsp90 inhibitors, which is under investigation in a broad range of clinical stages for the treatment of cancer.

Original languageEnglish
Pages (from-to)1855-1859
Number of pages5
JournalArchives of Pharmacal Research
Volume35
Issue number11
DOIs
StatePublished - Nov 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Recent updates on the development of ganetespib as a Hsp90 inhibitor'. Together they form a unique fingerprint.

Cite this